Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010; Elsevier BV; Volume: 21; Linguagem: Inglês
10.1093/annonc/mdq207
ISSN1569-8041
AutoresLucio Crinó, Walter Weder, Jan P. van Meerbeeck, Enriqueta Felip,
Tópico(s)Radiomics and Machine Learning in Medical Imaging
ResumoLung cancer represents the leading cause of cancer mortality worldwide, accounting for ∼1.2 million deaths each year.Improving survival in lung cancer is a major challenge for modern oncology considering that 5-year survival remains <15%, across all stages of disease and with <7% of patients alive 10 years after diagnosis.Because of the difficulties in significantly improving survival in locally advanced and metastatic non-small-cell lung cancer (NSCLC), diagnosis and treatment of early stages theoretically represent the most consistent possibility of modifying the outcome of NSCLC in terms of disease-free and overall survival.
Referência(s)